↓ Skip to main content

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Overview of attention for article published in Alzheimer's Research & Therapy, January 2011
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#19 of 1,019)
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
23 news outlets
twitter
3 tweeters
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
113 Dimensions

Readers on

mendeley
164 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
Published in
Alzheimer's Research & Therapy, January 2011
DOI 10.1186/alzrt75
Pubmed ID
Authors

François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine

Abstract

Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's permeability. Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells. As the brain is rich in mast cells, the therapeutic potential of masitinib as an adjunct therapy to standard care was investigated.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Russia 1 <1%
Egypt 1 <1%
Unknown 161 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 30 18%
Student > Master 28 17%
Student > Bachelor 21 13%
Student > Ph. D. Student 20 12%
Other 13 8%
Other 28 17%
Unknown 24 15%
Readers by discipline Count As %
Medicine and Dentistry 35 21%
Agricultural and Biological Sciences 20 12%
Neuroscience 18 11%
Pharmacology, Toxicology and Pharmaceutical Science 14 9%
Biochemistry, Genetics and Molecular Biology 10 6%
Other 29 18%
Unknown 38 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 170. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2020.
All research outputs
#154,345
of 19,790,383 outputs
Outputs from Alzheimer's Research & Therapy
#19
of 1,019 outputs
Outputs of similar age
#1,335
of 184,718 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 19,790,383 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,019 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them